BGA
HALO icon

Belmont Global Advisors’s Halozyme HALO Stock Holding History

Belmont Global Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-110,000
Closed -$949K – 76
2016
Q2 		$949K Buy
110,000
+77,200
+235% +$762K 0.91% 21
2016
Q1 		$311K Buy
+32,800
New +$309K 0.32% 47

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Belmont Global Advisors's HALO Position: Q2 2016 in Review

Belmont Global Advisors sold out of Halozyme (HALO) in Q2 2016, closing a stake of 30,000 shares — an estimated $296K sold.

Belmont Global Advisors first reported a position in HALO in Q4 2013 and held it in 7 quarters. The position peaked at $5.13M in Q4 2013. 161 funds tracked by Wall St. Rank hold HALO as of Q2 2016.

  • Belmont Global Advisors reported no remaining Halozyme position as of Q2 2016 after selling out during the quarter.
  • Belmont Global Advisors sold 30,000 Halozyme shares in Q2 2016, an estimated $296K.
  • Belmont Global Advisors first reported a position in Halozyme in Q4 2013 and held it in 7 quarters.
  • Belmont Global Advisors's Halozyme position peaked at $5.13M in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Halozyme as of Q2 2016.

Based on Belmont Global Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.